November 26, 2014
Eisai said on November 25 that its Brazilian subsidiary Eisai Laboratórios Ltda. has launched its anticancer agent Halaven (eribulin mesylate) in the country. This is Eisai’s first product to be marketed in Latin America by its local subsidiary. In Brazil,...read more